NEDO implements biojet fuel project, commercialization around 2030

NEDO has started a new program integrating former projects on microalgae biojet fuel (see: IHI and and biomass hydrothermal gasification with Showa Shell Oil, a company which commercializes jet fuel already. Partners will be 5 companies and the Japan Aerospace Exploration Agency JAXA. First, pure biojet fuel produced in pilot plants will have to conform to the standard ASTM D 7566. By further mixing with conventional petroleum-based jet fuel, the standard of the conventional fuel (ASTM D 1655) must be reached. NEDO expects commercialization around 2030.

NEDO news release, December 3, 2018

©NEDO Japan

Smart drones in a 4G LTE network as airborne police: Japan

NEDO, KDDI, Teradrone and SECOM, utilizing a 4 G LTE standard, conducted security experiments on multiple autonomously flying drones in Kanagawa Prefecture and succeeded in remote patrol security. By remote monitoring of camera images installed in the drones from the...

read more

Dai Nippon Printing: thin and stretchable skin displays

Based on developments at the University of Tokyo (JST ERATO Someya Project*) the company is developing a thin and stretchable skin display which it plans to market within 3 years**. In this device, 16 × 24 px micro light emitting diodes and stretchable wires are...

read more

Low-pressure ammonia synthesis makes progress

The group around Hideo HOSONO at Tokyo Institute of Technology has succeeded to further optimize a catalyst which permits to produce ammonia from molecular nitrogen and hydrogen at relatively mild conditions (400 C, 0.1 MPa = 1 bar). The best catalyst found so far is...

read more

Japan revitalisiert seine Seiden-Industrie

Japan hat eine lange Tradition für die Herstellung qualitativ sehr hochwertiger Naturseiden („Japanseide“), die z. B. zur Herstellung von Kimonos verwendet werden. Die japanische Seiden-Industrie, vor allem in den Präfekturen Gunma und Kumamoto beheimatet, erlebte...

read more

Japans Überalterung wird dramatische Folgen haben…

Die Überalterung der japanischen Gesellschaft wird enorme Auswirkungen auf Industrie, medizinische Versorgung, Pflege usw. haben. Ein von der Chiba University durchgeführtes Projekt erlaubt eine Computer-gestützte Vorschau auf die Folgen des Bevölkerungsrückgangs für...

read more

Solarenergie für Sensoren und Displays im T-Shirt

Ein Team des RIKEN und der Universität Tokio haben ultradünne organische Solarzellen entwickelt, die sich dehnen und waschen lassen. Eine nur 3 µ dicke Siegelfolie besteht aus einem Thiazolothiazol-/Naphthobisthiadiazol-Halbleitercopolymer, der beidseitig in Parylen...

read more


Full content list of all entries in News

Hydrogen peroxide content of breast milk may regulate the intestinal flora of babies

As studied by Associate Professor Kentaro NAGAOKA and colleagues at Tokyo University of Agriculture and Technology in mouse experiments, hydrogen peroxide produced in breast milk via amino acid oxidases acts as a gatekeeper for bacteria which gradually form the baby’s microbiome. Microorganisms such as lactic acid bacteria which have catalases preferentially enter the baby’s intestine.

RIKEN news release, November 16, 2018

Team at Osaka Prefecture University develops soft wearable pH sensor

©Osaka University

The group of Associate Professor Kuniharu TAKEI prepared a CCD structure on a flexible film creating a wearable device that could measure the pH value of sweat with high sensitivity. It also records skin temperature and thus can be developed into a daily health management tool. The charge transfer flexible pH sensor incorporates a structure that adjusts the Schottky barrier of the transistor material and the electrode. It also contains a flexible temperature sensor which corrects the electrochemical data. Sensitivity was 4 times higher compared to commercially available pH sensors, and pH value in sweat could be measured constantly for about 1 week by sticking the sensor to the skin like a bandage.

JST news release, November 13, 2018

Seikagaku Kogyo initiates test with novel post-surgery wound-healing material

SI – 449 is a crosslinked chondroitin sulfate developed as a medical device. It is an anti – adhesive material that spreads and swells after spraying it on surgical wound areas inside the abdominal cavity, etc., reducing postoperative adhesions. It is intended for use after laparotomy and endoscopic surgery.

Nikkei Biotech news release, November 12, 2018

Kyorin started PII for gene therapy of malignant pleural mesothelioma

Ad-SGE-REIC is a gene therapy in which the cancer-suppressing gene REIC (Reduced Expression in Immortalized Cells) discovered at Okayama University is incorporated into an adenovirus vector. When the REIC gene is forcibly expressed, cancer cells selectively cause cell death. According to the company, 10 interim analyzes will be carried out in 10 cases during phase II which was started in June.

Nikkei Biotech news release, November 7, 2018

NEDO starts new geothermal projects

Japan has one of the largest geothermal resource potentials in the world. Japanese resources are estimated at a maximum of 23.47 million kW. About 30 % of these resources are acidic hot water which is presently unused due to corrosion problems. NEDO will support new technologies which overcome this problems. The consortia formed include Fuji Electric, Nagoya University and the National Ocean R&D Organization.

NEDO news release, November 6, 2018

DSM and Chr.Hansen apply for registration of recombinant chymosins in Japan

The highest per capita consumption of cheese is in the world is in Greece, cheese intake per day is 85.2 g, and the intake of chymosin contained in cheese is estimated to about 5.6 μg. Japanese daily cheese intake is 6.5 g per capita and chymosin intake is estimated around 0.4 μg. In the 9th edition of food additives announced in February 2018 by the Ministry of Health, Labor and Welfare and the Consumer Agency, chymosin can be derived from “Ruminant Animal Stomach (Limited to Irpex lacteus), filamentous fungi (Cryphonectria parasitica, Mucor miehei, Mucor pusillus Lindt, Mucor spp., Rhizomucor miehei and Rhizomucor pusillus), yeast (limited to Kluyveromyces lactis) or bacteria (Bacillus cereus and Escherichia coli. DSM applied for Maxiren XDS, a new type of chymosin prepared by protein engineering and expressed in Kluyveromyces lactis. The enzyme is already approved in the USA. Chr. Hansen’s chymosin CHY-MAX-M is derived from camel prochymosin and expressed in Aspergillus awamori. The number of amino acid residues of camel chymosin in CHY-MAX M is 323, the same as that of bovine chymosin, and homology of amino acid residues is 85%. The specific activity of camel chymosin to cleave the Phe105– Met106 bond of κ-casein, essential for producing curd, is 1.7 fold higher than that of calf rennet.

Nikkei Biotech news release, November 1, 2018

NEDO-supported consortium builds large-scale hybrid storage battery system in Farrel, Lower Saxony

NEDO and Hitachi Kasei, Hitachi Power Solutions and NGK Insulators have completed a large-scale hybrid storage battery system in Farrel city, Lower Saxony, Germany and will start operation from November 1, 2018. The system consists of two types of storage batteries with different characteristics (lithium ion battery and sodium sulfur battery, total capacity 11.5 MW / 22.5 MWh). By making the system capable of high power, large capacity, chargeable and dischargeable, adjustment of the electricity supply-demand balance will be easier to reach and help to the stabilize input of wind energy into the power grid. A business model of new power trading based on this system will also be developed.

NEDO news release, October 31, 2018

Otsuka Pharmaceuticals signs agreement on cardiomyocyte technology with Adipo Medical Technology

Adipo Medical Technology Co. (AMT), an Osaka venture company, operates an AMED-supported project on the “Development of Multiple Lineage Precursor Cells from Allogeneic Adipose Tissue as a Cellular Medicine for the Treatment of Severe Heart Failure”, under project leadership of Akinobu Matsuyama at Fujita Medical University. Otsuka has announced that it has signed an agreement with AMT on a joint development of this technology including clinical trials.

Otsuka Pharmaceuticals news release, October 30, 2018

Lion reports positive impact on oral health using its saliva test system SMT

Lion Co. introduced its SMT test (salivary multi test) in May 2016. The test strip kit allows the simultaneous measurement of six saliva indicators within 5 minutes: cariogenic bacteria, pH and buffer capacity, leukocytes, proteins and ammonia, as an indicator related to oral cleanliness. After many field tests including 80 employees of Lion in Hirosaki City, it turned out that the test has raised awareness about good oral hygiene and has led to improvement of oral health as judged by dentists evaluation.

Lion Co.,

Daicel and Chitose to collaborate on C-4 chemicals from glycerol

Daicel has collaborative research with Nihon University, using wild-type bacteria, which produce erythritol from glycerin. Chitose is a specialist in bacterial mutagenesis and has developed a process for microbial butanediol production. Both companies will collaborate to improve the yield of various C-4 compounds from glycerol.

Nikkei Biotech news release, October 24, 2018

Japan will introduce charges for the use of plastic shopping bags from 2020

The Ministry of Environment has decided to stop free distribution of plastic shopping bags from 2020. Appropriate replacement of bags from renewable resources such as recycled materials, paper and biomass plastics will be supported. By 2030 it is aimed to have introduced biomass plastic at a level of about 2 million tons.

Nikkei Biotech news release, October 23, 2018

Tokai University Hospital to test osteoarthritis treatment by autologous cartilage cell sheet transfer

In a future doctor-led trial, cartilage of a patient’s knee is collected with an arthroscope, and self-laminated chondrocyte cell sheets (2 or more) are manufactured at the hospital’s cell culture center. At the time of high tibial oseotomy, defective tissue is excised and self-laminated chondrocyte sheets are transplanted following bone marrow stimulation. The number of subject cases is 20. The main endpoint is the effectiveness at 1 year after operation. Implementation period is 4 years for case registration, and 5 years for total observation period, totaling nine years.

Nikkei Biotech news release, October 23, 2018